Newsletters - December 1997

Newsletters - December 1997

Sabinsa Corporation will shortly introduce to the marketplace a new product derived from Fenugreek seeds. Fenugreek (Trigonella foenum-graecum, Family: Leguminosae) is native to North Africa and countries bordering the eastern Mediterranean and is widely cultivated in India. The seeds of Fenugreek are a condiment commonly used in Indian homes and are a rich source of fiber, particularly gel fiber. Gel fiber from Fenugreek resembles guar gum in chemical structure.

Sabinsa Corporation will shortly introduce to the marketplace a new product derived from Fenugreek seeds. Fenugreek (Trigonella foenum-graecum, Family: Leguminosae) is native to North Africa and countries bordering the eastern Mediterranean and is widely cultivated in India. The seeds of Fenugreek are a condiment commonly used in Indian homes and are a rich source of fiber, particularly gel fiber. Gel fiber from Fenugreek resembles guar gum in chemical structure. Pre-clinical and clinical studies have documented the anti-diabetic properties of the fiber-rich fraction of Fenugreek seeds. Diabetes mellitus is a disease characterized by high blood sugar levels. Diabetics also suffer from abnormal lipid profiles and are therefore prone to the development of coronary heart disease.

In Type I diabetics, the administration of the defatted fiber-rich seed significantly reduced fasting blood glucose levels and improved performance in the glucose tolerance test. Serum total cholesterol, LDL and VLDL cholesterol, as well as triglyceride levels, were significantly reduced, while the HDL levels remained unchanged. Similar effects were repeated in Type II diabetic patients2.

Pre-clinical studies indicate that the hypoglycemic effect of fenugreek is mediated through delayed gastric emptying and direct interference with glucose absorption3. The gel forming dietary fiber reduces serum cholesterol by decreasing the absorption of cholesterol and depleting cholesterol stores in the body by means of increased excretion of bile acids4.

Please contact Sabinsa Corporation for samples and further information.

References

  1. Sharma, R.D. et al (1990). Eur J. Clin. Nutr. 44:301
  2. Sharma, R.D. et al (1990). Nutr. Res. 10:731
  3. Madar, Z. (1984). Nutr. Rep. Intl. 29:1267
  4. Gee, J.M. et al (1983). Br J. Nutr. 50:215

    VISIT US

  • Sabinsa Europe GmbH
    Monzastrasse 4
    63225 Langen
    Germany

  • +49 6103 270 11 11
  • +49 6103 270 11 27
  • info@sabinsa.eu

CERTIFICATES

Certificate Logos Certificate Logos
Certificate Logos Certificate Logos

CONTACT US

Disclaimer

Please note that this website and information provided herein is not for final consumers of a finished food, beverage, dietary supplement product or cosmetic product, as the information contained herein does not refer to finished products for consumers.

The information provided on the website is intended only for producers of finished food, beverage, dietary supplement and cosmetic product.

The statements related to ingredients on the website, have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease.

The website and information herein are available in various countries across the world, and hence statements or product information including its classification may not be applicable in your country.

Information and statements provided on the website, shall not be construed as license to practice, or recommendations to infringe, any patents or other intellectual property rights of Sabinsa and others.

By browsing further, You understand the above terms.